World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0020936195
Reproduction Date:

Title: Acromegaly  
Author: World Heritage Encyclopedia
Language: English
Subject: André the Giant, Hyperpituitarism, Goitre, Endocrine disease, Growth hormones
Collection: Endocrine-Related Cutaneous Conditions, Growth Disorders, Growth Hormones, Neuroendocrinology, Pituitary Disorders
Publisher: World Heritage Encyclopedia


Classification and external resources
Facial aspect of a patient with acromegaly. The cheekbones are pronounced, the forehead bulges, the jaw is enlarged and facial lines prominent.
ICD-10 E22.0
ICD-9 253.0
OMIM 102200
DiseasesDB 114
MedlinePlus 000321
eMedicine med/27 derm/593
MeSH D000172

Acromegaly (; from Ancient Greek άκρος akros "extreme" or "extremities" and μεγάλος megalos "large") is a syndrome that results when the anterior pituitary gland produces excess growth hormone (GH) after epiphyseal plate closure at puberty. A number of disorders may increase the pituitary's GH output, although most commonly it involves a tumor called pituitary adenoma, derived from a distinct type of cell (somatotrophs).

Acromegaly most commonly affects adults in middle age,[1] and can result in severe disfigurement, complicating conditions, and premature death if unchecked. Because of its pathogenesis and slow progression, the disease is hard to diagnose in the early stages and is frequently missed for years until changes in external features, especially of the face, become noticeable.

Acromegaly is often associated with gigantism.


  • Signs and symptoms 1
  • Causes 2
    • Pituitary adenoma 2.1
    • Other tumors 2.2
  • Complications 3
  • Diagnosis 4
  • Treatment 5
    • Drugs 5.1
      • Somatostatin analogues 5.1.1
      • Dopamine agonists 5.1.2
      • Growth hormone receptor antagonists 5.1.3
    • Surgery 5.2
    • Radiation therapy 5.3
    • Choice of treatment 5.4
    • Prognosis upon treatment 5.5
  • Pseudoacromegaly 6
  • Notable cases 7
  • Fictional 8
  • References 9
  • External links 10

Signs and symptoms

Features that result from high level of GH or expanding tumor include:

  • Soft tissue swelling visibly resulting in enlargement of the hands, feet, nose, lips and ears, and a general thickening of the skin.
  • Soft tissue swelling of internal organs, notably the heart with attendant weakening of its muscularity, and the kidneys, also the vocal cords resulting in a characteristic thick, deep voice and slowing of speech
  • Generalized expansion of the skull at the fontanelle
  • Pronounced brow protrusion, often with ocular distension (frontal bossing)
  • Pronounced lower jaw protrusion (prognathism) with attendant macroglossia (enlargement of the tongue) and teeth spacing
  • Hypertrichosis, hyperpigmentation, and hyperhidrosis may occur in these patients.[2]:499
  • Acrochordon (skin tags)
  • Carpal tunnel syndrome


Pituitary adenoma

In over 90 percent of acromegaly patients, the overproduction of growth hormones is caused by a benign tumor of the pituitary gland, called an adenoma. These tumors produce excess growth hormones and, as they expand, compress surrounding brain tissues, such as the optic nerves. This expansion causes the headaches and visual disturbances that often accompany acromegaly. In addition, compression of the surrounding normal pituitary tissue can alter production of other hormones, leading to changes in menstruation and breast discharge in women and impotence in men because of reduced testosterone production.

There is a marked variation in rates of GH production and the aggressiveness of the tumor. Some adenomas grow slowly and symptoms of growth hormone excess are often not noticed for many years. Other adenomas grow rapidly and invade surrounding brain areas or the sinuses, which are located near the pituitary. In general, younger patients tend to have more aggressive tumors.

Most pituitary tumors arise spontaneously and are not genetically inherited. Many pituitary tumors arise from a genetic alteration in a single pituitary cell which leads to increased cell division and tumor formation. This genetic change, or mutation, is not present at birth, but is acquired during life. The mutation occurs in a gene that regulates the transmission of chemical signals within pituitary cells; it permanently switches on the signal that tells the cell to divide and secrete growth hormones. The events within the cell that cause disordered pituitary cell growth and growth hormone oversecretion currently are the subject of intensive research.

Other tumors

In a few patients, acromegaly is caused not by pituitary tumors but by tumors of the pancreas, lungs, and adrenal glands. These tumors also lead to an excess of GH, either because they produce GH themselves or, more frequently, because they produce GHRH (Growth Hormone Releasing Hormone), the hormone that stimulates the pituitary to make GH. In these patients, the excess GHRH can be measured in the blood and establishes that the cause of the acromegaly is not due to a pituitary defect. When these non-pituitary tumors are surgically removed, GH levels fall and the symptoms of acromegaly improve.

In patients with GHRH-producing, non-pituitary tumors, the pituitary still may be enlarged and may be mistaken for a tumor. Therefore, it is important that physicians carefully analyze all "pituitary tumors" removed from patients with acromegaly in order not to overlook the possibility that a tumor elsewhere in the hypoglycoma is causing the disorder.



Frequent blood sampling with serum GH measurement shows that in normal subjects (left panel) GH can fluctuate between undetectable levels (most of the time) and peaks of up to 30 μg/l (90 mIU/l), owing to the episodic nature of GH secretion, while in patients with acromegaly (an example is given on right panel), GH hypersecretion is continuous and GH never returns to undetectable levels.

If acromegaly is suspected, medical imaging and medical laboratory investigations are generally used together to confirm or rule out the presence of this condition.

IGF1 provides the most sensitive lab test for the diagnosis of acromegaly, and a GH suppression test following an oral glucose load, which is a very specific lab test, will confirm the diagnosis following a positive screening test for IGF1. A single value of the growth hormone (GH) is not useful in view of its pulsatality (levels in the blood vary greatly even in healthy individuals).
Magnetic resonance image of a pituitary macroadenoma that caused acromegaly with compression of the optic chiasm.
GH levels taken 2 hours after a 75 or 100 gram glucose tolerance test are helpful in the diagnosis: GH levels are suppressed below 1 μg/L in normal people, and levels higher than this cutoff are confirmatory of acromegaly.

Other pituitary hormones have to be assessed to address the secretory effects of the tumor as well as the mass effect of the tumor on the normal pituitary gland. They include TSH (thyroid stimulating hormone), gonadotropic hormones (FSH, LH), ACTH (adrenocorticotropic hormone), prolactin.

An MRI of the brain focusing on the sella turcica after gadolinium administration allows for clear delineation of the pituitary and the hypothalamus and the location of the tumor.


The goals of treatment are to reduce GH production to normal levels, to relieve the pressure that the growing pituitary tumor exerts on the surrounding brain areas, to preserve normal pituitary function, and to reverse or ameliorate the symptoms of acromegaly. Currently, treatment options include surgical removal of the tumor, drug therapy, and radiation therapy of the pituitary.


Somatostatin analogues

Site of action of the different therapeutic tools in acromegaly. Surgery, radiotherapy, somatostatin analogues and dopamine agonists act at the level of the pituitary adenoma, while GH-receptor antagonists act in periphery by blocking the growth hormone receptor and thus impairing the effects of GH on the different tissues.

The primary current medical treatment of acromegaly is to use somatostatin analogues – octreotide (Sandostatin) or lanreotide (Somatuline). These somatostatin analogues are synthetic forms of a brain hormone, somatostatin, which stops GH production. The long-acting forms of these drugs must be injected every 2 to 4 weeks for effective treatment. Most patients with acromegaly respond to this medication. In many patients, GH levels fall within one hour and headaches improve within minutes after the injection. Octreotide and lanreotide are effective for long-term treatment. Octreotide and lanreotide have also been used successfully to treat patients with acromegaly caused by non-pituitary tumors.

Somatostatin analogues are also sometimes used to shrink large tumors before surgery.

Because octreotide inhibits gastrointestinal and pancreatic function, long-term use causes digestive problems such as loose stools, nausea, and gas in one third of patients. In addition, approximately 25 percent of patients develop gallstones, which are usually asymptomatic. In some cases, octreotide treatment can cause diabetes due to the fact that somatostatin and its analogues can inhibit the release of insulin. On the other hand, scientists have found that in some acromegaly patients who already have diabetes, octreotide can reduce the need for insulin and improve blood sugar control.

Dopamine agonists

For those who are unresponsive to somatostatin analogues, or for whom they are otherwise contraindicated, it is possible to treat using one of the dopamine agonists, Bromocriptine (Parlodel) or Cabergoline. These have the advantage of being tablets rather than injections, and cost considerably less. These drugs can also be used as an adjunct to somatostatin analogue therapy. They are most effective in those whose pituitary tumours cosecrete prolactin. Side effects of these dopamine agonists include gastrointestinal upset, nausea, vomiting, light-headedness when standing, and nasal congestion. These side effects can be reduced or eliminated if medication is started at a very low dose at bedtime, taken with food, and gradually increased to the full therapeutic dose. However, bromocriptine lowers GH and IGF-1 levels and reduces tumor size in fewer than half of patients with acromegaly. Some patients report improvement in their symptoms although their GH and IGF-1 levels still are elevated.

Growth hormone receptor antagonists

The latest development in the medical treatment of acromegaly is the use of growth hormone receptor antagonists. The only available member of this family is pegvisomant (Somavert). By blocking the action of the endogenous growth hormone molecules, this compound is able to control disease activity of acromegaly in virtually all patients. Pegvisomant has to be administered subcutaneously by daily injections. Combinations of long-acting somatostatin analogues and weekly injections of pegvisomant seem to be equally effective as daily injections of pegvisomant.


Surgery is a rapid and effective treatment, of which there are two alternative methods. The first method, a procedure known as Endonasal Transphenoidal surgery, involves the surgeon reaching the pituitary through an incision in the nasal cavity wall. The wall is reached by passing through the nostrils with microsurgical instruments. The second method is Transsphenoidal surgery during which an incision is made into the gum beneath the upper lip. Further incisions are made to cut through the septum to reach the nasal cavity, where the pituitary is located. Endonasal Transphenoidal surgery is a less invasive procedure with a shorter recovery time than the older method of Transphenoidal surgery, and the likelihood of removing the entire tumor is greater with reduced side-effects. Consequently, Endonasal Transphenoidal surgery is often used as a first option, with Transphenoidal and other treatments, such as medicinal therapy or radiostatic neurosurgery, being used to reduce the remaining adverse effects of the remaining tumor.

These procedures normally relieve the pressure on the surrounding brain regions and lead to a lowering of GH levels. Surgery is most successful in patients with blood GH levels below 40 ng/ml before the operation and with pituitary tumors no larger than 10 mm in diameter. Success depends on the skill and experience of the surgeon. The success rate also depends on what level of GH is defined as a cure. The best measure of surgical success is normalization of GH and IGF-1 levels. Ideally, GH should be less than 2 ng/ml after an oral glucose load. A review of GH levels in 1,360 patients worldwide immediately after surgery revealed that 60 percent had random GH levels below 5 ng/ml. Complications of surgery may include cerebrospinal fluid leaks, meningitis, or damage to the surrounding normal pituitary tissue, requiring lifelong pituitary hormone replacement.

Even when surgery is successful and hormone levels return to normal, patients must be carefully monitored for years for possible recurrence. More commonly, hormone levels may improve, but not return completely to normal. These patients may then require additional treatment, usually with medications.

Radiation therapy

Radiation therapy has been used both as a primary treatment and combined with surgery or drugs. It is usually reserved for patients who have tumor remaining after surgery. These patients often also receive medication to lower GH levels. Radiation therapy is given in divided doses over four to six weeks. This treatment lowers GH levels by about 50 percent over 2 to 5 years. Patients monitored for more than 5 years show significant further improvement. Radiation therapy causes a gradual loss of production of other pituitary hormones with time. Loss of vision and brain injury, which have been reported, are very rare complications of radiation treatments.

Choice of treatment

No single treatment is effective for all patients. Treatment should be individualized depending on patient characteristics, such as age and tumor size. If the tumor has not yet invaded surrounding brain tissues, removal of the pituitary adenoma by an experienced neurosurgeon is usually the first choice. After surgery, a patient must be monitored for a long time for increasing GH levels. If surgery does not normalize hormone levels or a relapse occurs, a doctor will usually begin additional drug therapy. The current first choice is generally octreotide or lanreotide. However, bromocriptine or cabergoline are much cheaper and easier to administer. With both types of medication, long-term therapy is necessary because their withdrawal can lead to rising GH levels and tumor re-expansion. Radiation therapy is generally used for patients whose tumors are not completely removed by surgery; for patients who are not good candidates for surgery because of other health problems; and for patients who do not respond adequately to surgery and medication.

Prognosis upon treatment

Upon successful treatment, symptoms and complications generally improve substantially or disappear, including headaches, visual disturbances, excess sweating and diabetes.[4] Soft tissue swellings generally decrease and acromegaly-associated facial features gradually return towards normal although this may take some time.[4] Life expectancy after the successful treatment of early acromegaly is equal to that of the normal population.[4]


Pseudoacromegaly is a condition with the usual acromegaloid features but without an increase in growth hormone and IGF-1. It is frequently associated with insulin resistance.[5] Cases have been reported due to minoxidil at an unusually high dose.[6] It can also be caused by a selective post-receptor defect of insulin signalling, leading to the impairment of metabolic but preservation of mitogenic signalling.[7]

Notable cases

Famous patients, all but three, Maurice Tillet, Wallace Stevens, and Antonio Silva) standing in excess of 2.00 metres (6.6 feet). Note: If acromegaly is developed in teenage years, it’s called gigantism and results in excess height. However, when acromegaly commences in adulthood, the bones have already set and the body doesn’t usually grow taller.

  • Kevyn Aucoin, famous celebrity make-up artist, was said to have had a rare pituitary tumor. He had been suffering from acromegaly resulting from the tumor for much of his life, but it had gone undiagnosed. Aucoin died on May 7, 2002 at Westchester Medical Center in Valhalla, New York of kidney and liver failure.
  • Mary Ann Bevan, an Englishwoman, variously exhibited in Coney Island and the World's Fair in the early 20th century, being referred to as 'the world's ugliest woman'.[8]
  • Charles Byrne, also known as The Irish Giant, 2.31 m (7 ft 7 in).
  • Primo Carnera, professional boxer, wrestler, and World Heavyweight champion, 2 m (6 ft 7 in).[9]
  • Ted Cassidy, best known for playing Lurch on The Addams Family TV series.
  • Dalip Singh Rana a/k/a The Great Khali, professional wrestler, actor, former police officer, 2.16 m (7 ft 1 in).
  • William R. Golden, a certified public accountant from Roswell, New Mexico was one of the first people treated with massive doses of the psychotropic drug Bromocriptine (parlodel) in the 1980s. Golden volunteered to be treated with the drug which was, at the time, only approved for people in the later stages of Parkinson's disease. Complications including nausea, hallucinations and changes to photo receptors indicated use of the drug at lower levels. Post remission complications included amnesia, confusion, depression, a weakened immune system and rapid-onset (Type II) insulin-dependent diabetes. However, the overall success of his treatment led to extensive use of the drug to this day. 2 m (6 ft 7 in)
  • Rondo Hatton, character horror actor in the 1930s and 1940s[10]
  • Richard Kiel, actor; "Jaws" from two James Bond movies and Mr. Larson in Happy Gilmore.[11] He grew up to 7 ft 1½ in, but was slightly under 7 ft in his later years due to age and injury.
  • [13]
  • Cornelius Magrath, known as The Irish Giant.
  • Maximinus I, Roman Emperor from 235 to 238.
  • James McLeay, professional SANFL player, suffers from low grade acromegaly, 2.1 m, 120 kilograms.[14]
  • Pío Pico, the last Mexican Governor of California (1801–1894), manifested acromegaly without gigantism between at least 1847 and 1858. Some time after 1858 signs of the growth hormone-producing tumor disappeared along with all the secondary effects the tumor had caused in him. He looked normal in his 90's.[15] His remarkable recovery is likely an example of spontaneous selective pituitary tumor apoplexy.[16]
  • Anthony Robbins, motivational speaker.
  • Paul Benedict, played Harry Bentley in The Jeffersons
  • André the Giant (born André Rousimoff), professional wrestler and actor[17][18] 2.13 m (7') tall after back surgery; his original wrestling stats listed him at 2.23 m (7'4"). He died at the age of 46 and weighed 520 pounds (240 kg). (He chose not to be treated and died from cardiac complications of the disease.)
  • Antonio Silva, mixed martial artist, currently competing at heavyweight in the Ultimate Fighting Championship. Silva stands at 6'4" and weighs in for fights at 264 lbs.
  • Sir Archibald Levin Smith, British judge.[19]
  • Carel Struycken, Dutch actor, 2.13m (7'0").[20]
  • Maurice Tillet, "The French Angel", professional wrestler 1940s
  • Paul Wight, professional wrestler, also known by the ring names "Big Show" and, earlier in his career, "The Giant." Stands 7' or 2.1 m.[21] Wight underwent surgery on his pituitary gland in the early 1990s, which halted the progress of the condition.
  • John Bloom[22] actor; best known for his role in Bachelor Party as Milt, the Indian pimp's enforcer and bodyguard.
  • Neil McCarthy, classic British actor, known for his craggy looks, died of motor neurone disease.


  • It has been suggested that the character Punch from Punch and Judy was originally a caricature of an Acromegaly sufferer.[23]
  • In the film The Monster Maker (1944), a scientist creates a "cure" for acromegaly. When the daughter of a concert pianist rejects his advances, he injects the pianist with a drug that causes acromegaly, in order to extort both father and daughter for the cure.
  • The islanders in the film Doomwatch (1972) are said to have the condition.
  • A scientist Eric Jacobs in the film Tarantula_(film) (1955) died from acromegaly after being injected with a drug which induced it.


  1. ^ "Acromegaly and Gigantism". Archived from the original on 5 November 2010. Retrieved 2010-10-26. 
  2. ^ James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. ISBN 0-7216-2921-0.
  3. ^ Renehan AG, O'Connell J, O'Halloran D, et al. (2003). "Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications". Horm. Metab. Res. 35 (11-12): 712–25.  
  4. ^ a b c Acromegaly - Patient information from Centre for Diabetes and Endocrinology at The Royal Berkshire NHS Foundation Trust. January 2011
  5. ^ Yaqub A, Yaqub N (2008). "Insulin-mediated pseudoacromegaly: a case report and review of the literature". W V Med J 104 (5): 12–5.  
  6. ^ Nguyen KH, Marks JG (June 2003). "Pseudoacromegaly induced by the long-term use of minoxidil". J. Am. Acad. Dermatol. 48 (6): 962–5.  
  7. ^ "Insulin-mediated "pseudoacromegaly".". Retrieved 05/12/2013. 
  8. ^ National Fairground Archive. "Extracts from World's Fair, 1931-1940: Death of the World's Ugliest Woman". Accessed 12 January 2014.
  9. ^ "Boxer vs. Wrestler Primo Carnera". Retrieved 2012-06-08. 
  10. ^ "Rondo Hatton by Barry Brown". Retrieved 2010-07-26. 
  11. ^ "Richard "Jaws" Kiel, Famed Bond Movie Villain, Raises Awareness Oflife-Threatening Hormone Disorder". Retrieved 2010-07-26. 
  12. ^ Link text, Historical footnote in regards to Marfan's.
  13. ^ Link text, Hypokinetic Constitution.
  14. ^ Archived May 4, 2010 at the Wayback Machine
  15. ^ Login IS, Login J (July 2008). "Governor Pio Pico, the monster of more: lessons in neuroendocrinology". Pituitary 13 (1): 80–6.   Open Access;
  16. ^ Nawar RN, AbdelMannan D, Selman WR, Arafah BM (2008). "Pituitary tumor apoplexy: a review". J Intensive Care Med 23 (2): 75–90.  
  17. ^ "Andre the Giant: Bio". Archived from the original on 2008-01-10. Retrieved 2007-10-16. 
  18. ^ "André the Giant official website". Archived from the original on 4 July 2007. Retrieved 2007-07-08. 
  19. ^ "Famous Acromegalics and Our Member Photos". Retrieved 2010-07-26. 
  20. ^ Carel Struycken - IMDb
  21. ^ Levitt, Stephanie (1972-02-08). "The show must go on: in basketball, professional wrestling and life in general, Paul Wight has had his share of triumphs and disappointment | Wrestling Digest | Find Articles at BNET". Retrieved 2010-07-26. 
  22. ^ John Bloom - Biography - IMDb
  23. ^ "report on Punch and Acromegaly". BBC News. 2006-09-05. Retrieved 2010-10-26. 

External links

  • New guidelines for the treatment of acromegaly, a serious growth hormone disorder -
  • Endocrine and Metabolic Diseases Information Service
  • A webinar series
  • A satellite site of the Pituitary Network Association
  • Millions might unknowingly suffer from growth-hormone disorder -
  • Acromegaly and Gigantism (a very comprehensive article)
  • Acromegaly and Gigantism (Image of a patient with macroglossia - enlargement of the tongue)
  • The Pituitary Foundation, Helping to support pituitary patients including patients with Acromegaly
  • Acromegaly Clinical Trials from U.S. National Institutes of Health
  • Acromegaly info from: U.S. National Library of Medicine, U.S. Department of Health and Human Services & National Institutes of Health
  • Acromegaly Info from Novartis Pharmaceuticals Corporation
  • The Pituitary Network Association --
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.